[Problem to be solved] To provide a pharmaceutical composition for treating a disease caused by an RNA virus.

[Solution] A pharmaceutical composition for a disease caused by an RNA virus or an inhibitor of RNA virus replication, comprising retinoic acid receptor responder protein 3 and/or an mTOR inhibitor.

Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.

Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.

A rapid amplification method for a nucleic acid of hepatitis B virus, comprises the following steps: mixing a sample containing hepatitis B virus with a nucleic acid releasing agent, and adding a PCR premix to obtain a reaction solution, the PCR premix comprising deoxyribonucleoside triphosphate, an upstream primer as shown in the sequence SEQ ID NO: 1, a downstream primer as shown in the sequence SEQ ID NO: 2, a DNA polymerase and an amplification buffer; placing the reaction solution in a PCR reaction tube so that the reaction solution is in a form of a thin film with a thickness of 0.1 mm or less; performing PCR amplification under the following reaction condition: pre-denaturation at 90 to 100° C. for 10 s to 600 s, denaturation at 90 to 100° C. for 0 to 1 s, and annealing and extending at 50-65° C. for 0 to 1 s.

Provided herein are compositions, systems, and methods for assessing and monitory disease stage and phases, predicting likelihood of disease progression, and predicting and monitoring responses to disease therapies (e.g., in HBV infection).

Aspects of the present invention provide novel multi-targeted microbiological screening and monitoring methods having substantial utility for monitoring and control of microbial growth and contaminants, microbiological processes, predictive microbiology, and for exposure and risk assessment. Microbial markers shared by both target and index microbes are used in novel methods for microbial monitoring, monitoring of microbial performance potential, trend analysis, and statistical process control (SPC) in processes or systems that are receptive to a plurality of genetically distinct microbes.

The invention provides methods for isolating DNA from a blood sample collected into tubes containing a rapid clot activator, which involves the use of a lysis buffer comprising an alcohol.

The disclosure is directed to methods, kits, and compositions, for amplifying and detecting a human hepatitis B virus (HBV) in a sample, which comprises a variety of combinations of forward oligonucleotide primers, reverse oligonucleotide primers, and oligonucleotide probes.

Methods for screening for a cancer condition in a subject are provided. A biological sample from the subject is obtained. The sample comprises cell-free nucleic acid from the subject and potentially cell-free nucleic acid from a pathogen in a set of pathogens. The cell-free nucleic acid in the biological sample is sequenced to generate a plurality of sequence reads from the subject. A determination is made, for each respective pathogen in the set of pathogens, of a corresponding amount of the plurality of sequence reads that map to a sequence in a pathogen target reference for the respective pathogen, thereby obtaining a set of amounts of sequence reads, each respective amount of sequence reads in the set of amounts of sequence reads for a corresponding pathogen in the set of pathogens. The set of amounts of sequence reads is used to determine whether the subject has the cancer condition.

A probe for detecting hepatitis B virus and a method for detecting an insertion site of hepatitis B virus at high efficiency based on the analysis method of next-generation sequencing using the probe is disclosed. A probe can be provided that is capable of confirming the insertion site of HBV in the human genome with a possibility of developing into liver cancer. In addition, by applying the probe to the analysis method of next-generation sequencing, HBV insertion sites in the human genome can be analyzed at low cost and high efficiency.